History
Thyroid cancer is a collective term for cancers that arise in a small endocrine gland called the thyroid. Located at the front of the neck, the thyroid makes hormones that affect the body's energy metabolism, body temperature, and heart rate. Nodules (lumps) arising in this area have long been known, and in the past they were sometimes perceived together with diseases that cause swelling of the neck as a single entity. As pathology, which distinguishes tissues under the microscope, advanced, it began to be established that tumors of the thyroid are not of one type but of several types with very different prognoses. In particular, distinguishing cancers with different cells of origin or different degrees of differentiation, such as papillary, follicular, medullary, and anaplastic carcinoma, became key to changing treatment strategies.
Changes in diagnostic tools also greatly affected this history. In the past, cancer was often found only when a large mass could be felt by hand, but as ultrasound and fine-needle aspiration became commonplace, many small cancers without symptoms began to be diagnosed. This change created the phenomenon of incidence appearing to increase sharply. On the one hand, opportunities for early detection and treatment increased, but on the other hand, it led to discussion of the problem of overdiagnosis and overtreatment, in which even cancers that grow biologically very slowly are treated under the name of cancer.
In recent studies, the strategy of choosing active surveillance instead of surgery for some low-risk papillary thyroid cancers is being examined, and "personalization of treatment," such as minimally invasive treatment or reducing the extent of surgery, is becoming established as an important trend. Attempts also continue to explain why cancers with the same name can follow different courses by using histological classification and molecular biological classification together.
Causes
The cause of thyroid cancer cannot be explained in a single way. It is more accurate to understand it as several environmental and individual factors overlapping to increase risk. The most consistently mentioned risk factor is exposure of the head and neck area to radiation at a young age. The risk may increase in people who received radiation therapy for treatment purposes or were exposed to radioactive substances (e.g., radioactive iodine) in certain environments. However, in real life such exposure is uncommon for most people, and the situations in which risk increases are limited.
Cancer is observed to be found more frequently in people with an enlarged thyroid (goiter) or nodules. However, having a nodule does not by itself mean cancer. Thyroid nodules are very common in adults, and the vast majority are benign. The risk may be higher if a family member has thyroid cancer or if there is a specific hereditary syndrome. There are also observations that weight gain and obesity are related to risk, and associations with sex and the hormonal environment have also been studied. The fact that thyroid cancer is more common in women supports these discussions, but it cannot be explained simply by a single hormone.
Recent studies emphasize the perspective of separating the reasons for the increase in thyroid cancer "diagnoses" into causes (onset) and the diagnostic environment (detection). If more small nodules are found by ultrasound and the criteria for biopsy are broadened, diagnoses can increase. Therefore, in explaining the cause, changes in the social and medical environment must be considered along with individual risk factors.
Genetic Epidemiology
Genetic epidemiology is the field that looks at the population level at "which genetic changes are more common in whom, and how those changes affect the occurrence and course of the disease." In thyroid cancer, the representative genetic changes differ depending on the type of cancer. In papillary thyroid cancer, specific genetic changes that cause cell growth signals to be excessively switched on are observed relatively often. In follicular cancer, genetic changes in other pathways, and in medullary cancer, genetic changes related to the neuroendocrine nature of the cells, emerge as central.
In hereditary syndromes such as familial medullary thyroid cancer or multiple endocrine neoplasia, specific gene variants are inherited from a parent and the risk of thyroid cancer increases greatly. In such cases, management involves finding carriers through family testing before symptoms develop and considering preventive surgery or intensive follow-up. On the other hand, most papillary and follicular thyroid cancers occur "sporadically," and genetic changes that arise only within the cancer tissue (somatic mutations) are more common.
Recent studies emphasize that genetic changes are not simply a matter of "present/absent" but can be clues that predict the behavior of the cancer (likelihood of lymph node metastasis, invasion of surrounding tissue, treatment response, recurrence risk). However, diagnosis and treatment cannot be determined by genetic information alone, and it is important to integrate it with clinical information such as ultrasound findings, cytology results, the patient's age and stage, and surgical findings.
General Epidemiology
General epidemiology deals with how often a disease occurs in a population, in which people it is more common, and how it changes over time. Thyroid cancer is among the relatively commonly diagnosed cancers, but its mortality is known to be low compared with cancers of other organs. In particular, papillary thyroid cancer, the most common type, often has very good long-term survival after treatment. On the other hand, rare but very aggressive types such as anaplastic carcinoma also exist, and although the impact of such types on overall prognostic statistics is limited, they are clinically very important.
The age distribution differs by type of cancer. Papillary cancer is found even in relatively young adults, and follicular cancer tends to be diagnosed at relatively older ages. Anaplastic cancer is usually found in older adults. By sex, diagnosis is more common in women, but there are also observations that when it is found in men it is often more advanced or carries a higher risk of recurrence, so it does not end with simply "women get it more."
An important feature is that incidence has been reported to have increased over the past several decades. Much of this increase is often explained by increased use of imaging (especially ultrasound) and increased detection of small nodules. Recent studies report that the increase in very small, low-risk papillary cancers drove the overall increase, and accordingly the trend of adjusting treatment policy to each patient's risk level is being strengthened.
Pathogenesis
The pathogenesis of thyroid cancer can be understood as a process in which normal thyroid cells, under the influence of genetic changes and the microenvironment, begin uncontrolled proliferation and, over time, acquire the ability to invade surrounding tissue or spread to other organs. This process unfolds differently for each type of cancer. Papillary and follicular thyroid cancers mainly start in thyroid follicular cells and belong to the relatively "well-differentiated" cancers. Being well differentiated means that they retain the character of normal thyroid cells to some extent, which is why they often grow slowly and respond well to treatment.
Medullary cancer starts in the C cells of the thyroid (cells related to a hormone called calcitonin), which have a different origin from follicular cells. Therefore, blood test markers, patterns of spread, and the choice of treatment drugs can differ from those for papillary and follicular cancer. Anaplastic cancer is a form in which differentiation has almost disappeared, and the cells tend strongly to grow very rapidly and invade surrounding tissue aggressively.
Recent studies discuss that genetic changes may accumulate step by step as a thyroid nodule progresses to cancer, and that different cell populations may coexist even within the same tumor. Research is also increasing showing that the tumor microenvironment, such as immune cells, fibrous tissue, and blood vessels, can affect growth and metastasis, and this understanding forms the background for new treatment approaches such as targeted therapies and immunotherapy.
Symptoms
Thyroid cancer often has no symptoms in its early stages. For this reason, it is common for a nodule to be found incidentally on a neck ultrasound performed at a health checkup or for another reason, or on imaging of the neck or chest. If symptoms develop, the most common form is a lump felt at the front of the neck, or a sense that the neck is enlarged when looking in the mirror or at photos. However, a palpable lump does not mean cancer, and benign nodules are also common.
When the cancer progresses or irritates surrounding structures, sensations such as a foreign-body feeling in the throat, difficulty swallowing, neck pain, or pain radiating to the ear may accompany it. A persistent voice change or hoarseness raises the possibility that the vocal cord nerve has been affected. Shortness of breath or a persistent cough can also rarely appear, but because these symptoms can also occur in other common diseases, thyroid cancer cannot be confirmed by "symptoms alone."
When there is lymph node metastasis, the lymph nodes at the side of the neck may enlarge and be palpable. In particular, it is not uncommon for lymph node metastasis to be found together with papillary cancer in younger people. Conversely, with very aggressive cancers (e.g., anaplastic cancer), compression symptoms such as difficulty breathing and difficulty swallowing can be prominent, along with a mass that grows rapidly within a short period.
Signs
Signs are objective findings that the examiner can observe or measure. The most common sign in thyroid cancer is a nodule in the neck. On palpation (feeling with the hands), nodules that are hard, have irregular borders, or feel fixed to the surrounding tissue are examined more carefully. However, it is difficult to distinguish benign from malignant by palpation alone. When lymph nodes are enlarged and are abnormally hard in shape or clustered together, metastasis can be suspected.
Ultrasound is the key tool for confirming signs. On ultrasound, if a nodule appears very dark (hypoechoic), shows microcalcifications, is taller than it is wide, has blurred borders, or appears to infiltrate its surroundings, the risk is assessed as high. Conversely, nodules with a large cystic component that are smooth and uniform are considered relatively likely to be benign. However, because exceptions can always occur, the basic principle is to judge ultrasound findings together with cytology and biopsy.
A normal thyroid hormone level on a blood test does not mean that there is no cancer, and an abnormal level does not mean that there is cancer. However, in medullary cancer, blood calcitonin can help with diagnosis and follow-up. Recent studies increasingly report that molecular testing (genetic testing) can help assess risk in nodules with indeterminate cytology results.
Screening
Screening is a strategy for finding disease early in people without symptoms. For thyroid cancer, the consensus has been that screening of the general population is not recommended. The reason is that thyroid ultrasound can find many very small cancers, but many of them may grow very slowly or never cause problems during a lifetime, so detection itself can actually increase the risk of unnecessary surgery and complications.
However, this does not mean that "no one is tested." When a lump is felt in the neck, when symptoms such as voice change persist, or when a nodule with risk features has already been found on ultrasound, tests for diagnosis are needed. In addition, for people who received radiation therapy to the head and neck in childhood or in whom a strong hereditary risk such as familial medullary cancer has been confirmed, a level of follow-up different from that for the general public is discussed. Such cases are closer to "management of high-risk groups" than to screening.
Recent studies continue efforts to identify the conditions under which active surveillance of low-risk small papillary cancers can be applied safely, and to improve ultrasound risk classification systems to reduce unnecessary biopsies. The key is not to find as many cases as possible indiscriminately, but to pick out well the diseases that threaten life or require treatment.
Diagnosis
Diagnosis of thyroid cancer usually proceeds in the sequence "detection of a nodule → ultrasound evaluation → fine-needle aspiration if needed → integration of pathology results and clinical information." Ultrasound evaluates the size, shape, internal composition, and presence of calcification of the nodule, its relationship with surrounding tissue, and the condition of the lymph nodes. Nodules that appear low-risk and are small are sometimes simply observed for a certain period.
Fine-needle aspiration is a test in which cells are drawn from the nodule with a thin needle and examined under a microscope. It is relatively simple and safe and is often performed in an outpatient setting. The results may be divided into categories such as clearly cancer, benign, atypical, and suspected follicular neoplasm. In particular, with follicular lesions it is sometimes difficult to determine cancer versus benign from cells alone, so in some cases the final diagnosis is made only after surgical removal, by checking for capsular or vascular invasion.
When cancer is diagnosed or strongly suspected, additional imaging may be performed for staging. After surgery, blood marker tests and ultrasound follow-up are commonly used to evaluate recurrence risk and treatment response. Recent studies show a broadening of the approach of estimating the likelihood of malignancy more precisely through molecular testing when cytology is indeterminate.
Treatment
Surgery is the center of thyroid cancer treatment. Depending on the type, size, and location of the cancer, whether there is invasion of surrounding tissue, whether there is lymph node metastasis, and the patient's age and comorbidities, it is decided whether to remove only part of the thyroid (lobectomy) or all of it (total thyroidectomy). If lymph node metastasis is confirmed, neck lymph node dissection may be performed together. After surgery, thyroid hormone must be supplemented with medication, and in some cases a strategy of keeping the hormone "slightly high" is used to suppress the growth of remaining cancer cells.
In well-differentiated thyroid cancers such as papillary and follicular cancer, radioactive iodine therapy may be used as additional treatment. Radioactive iodine uses the property of thyroid cells to absorb iodine to treat remaining thyroid tissue or microscopic metastases. However, it is not needed for every patient, and it is sometimes omitted when the risk of recurrence is low. Medullary cancer differs in its iodine-absorbing properties, so radioactive iodine therapy does not help.
For advanced or recurrent cancer, targeted therapies, anticancer drugs, or radiation therapy may be considered. Recent studies are discussing the safety and conditions of strategies of postponing surgery and actively observing low-risk small papillary cancers, or of reducing the extent of surgery.
Prognosis
The prognosis of thyroid cancer depends greatly on the type of cancer and the stage (extent of spread). Papillary cancer, the most common type, generally has a very good prognosis, and many patients live for a long time without recurrence. Follicular cancer also generally has a good prognosis, but the possibility of spreading to distant organs through the blood vessels is mentioned relatively more often. Medullary cancer varies greatly by stage, and whether there are lymph node or distant metastases at diagnosis and whether complete surgical removal is possible are important. Anaplastic cancer is known to be very aggressive with a poor prognosis, so rapid treatment decisions are needed immediately upon diagnosis.
When assessing prognosis, not only the "survival rate" but also recurrence risk and quality of life are considered together. Postoperative complications (vocal cord paralysis, hypocalcemia, etc.), hormone medication that must be taken for life, side effects after radioactive iodine therapy, and the burden of repeated follow-up tests can affect daily life. That is why risk-based treatment that "reduces overtreatment while maintaining safety" has recently been emphasized.
Recurrence is monitored by integrating the extent of surgery, whether there was lymph node metastasis, pathology findings, changes in blood markers, follow-up ultrasound findings, and other factors. Recent studies increasingly report that molecular biological features can better predict recurrence risk, and accordingly the direction of personalizing treatment intensity is being strengthened.
Prevention
Prevention of thyroid cancer is difficult to summarize as "one definitive lifestyle rule." However, the directions that can reduce risk can be divided into a few categories. The first is reducing unnecessary radiation exposure. It is important that medical imaging be performed when needed, and especially in children and adolescents, it is better to decide on radiation exposure of the head and neck as carefully as possible. Because radiation for treatment purposes is given when the benefits outweigh the risks, the key is to follow appropriate indications and protection principles rather than fearing it in itself.
The second is prevention strategies in high-risk groups. When a specific genetic variant is identified, as in familial medullary cancer, the risk for the individual and family is assessed through genetic counseling, and in some cases strong preventive measures such as prophylactic thyroidectomy can be considered. The third is that "reducing overdiagnosis" can also be seen as prevention in a broad sense. Indiscriminately performing ultrasound on people without symptoms and at average risk to find small nodules can increase the burden of treatment without reducing cancer deaths.
In terms of lifestyle, since an association with obesity has been reported, maintaining a healthy weight and managing overall metabolic health can be helpful. However, this has not been established as a specific preventive method targeting thyroid cancer alone, and it is more accurate to understand it as part of overall health management.